Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMARIN CORP PLC\UKAMRN · Entity 5970 | Director | April 18, 2025 | April 23, 2025 |
| Innoviva, Inc.INVA · Entity 4679 | Director | May 04, 2026 | May 06, 2026 |
| NOVELION THERAPEUTICS INC.NVLN · Entity 152369 | Director | August 09, 2018 | August 13, 2018 |
| OneIM Acquisition Corp.OIM · Entity 5734 | Director | January 13, 2026 | January 13, 2026 |
| Sarissa Capital Acquisition Corp.SRSA · Entity 145567 | Senior Managing Director | October 20, 2020 | October 20, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMARIN CORP PLC\UK
Report date April 18, 2025 · Filed April 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 401 |
Last balance in matching sequence
After 2025-04-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-04-18 · Exercise / conversion · Acquired 838 · Balance 838 F1: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F2: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted an award that vests in three equal installments on each of April 18, 2025, April 18, 2026 and April 18, 2027 F3: Not applicable Row 2 · 2025-04-18 · Tax withholding · Disposed 437 · Balance 401 F1: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F4: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,676 |
Reported balance
After 2025-04-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-18 · Exercise / conversion · Acquired 838 · Balance 1,676 F5: Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion. F1: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F2: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted an award that vests in three equal installments on each of April 18, 2025, April 18, 2026 and April 18, 2027 F3: Not applicable |
Filing footnotes · ownership attribution and instrument terms
F1: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change.
F2: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted an award that vests in three equal installments on each of April 18, 2025, April 18, 2026 and April 18, 2027
F3: Not applicable
F4: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
F5: Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion.
Innoviva, Inc.
Report date May 04, 2026 · Filed May 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 140,492 |
Reported balance
After 2026-05-04 transaction · row 1
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 9,786 · Balance 140,492 F1: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability. |
| Non-statutory Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $22.99 · Expires 2036-05-03 | Direct | 10,000 |
Reported balance
After 2026-05-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-04 · Grant · Acquired 10,000 · Balance 10,000 F1: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability.
NOVELION THERAPEUTICS INC.
Report date August 09, 2018 · Filed August 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.33 · Expires 2028-08-09 | Direct | 10,000 |
Reported balance
After 2018-08-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-08-09 · Grant · Acquired 10,000 · Balance 10,000 F1: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date. F2: The option shall vest in twelve equal monthly installments, beginning one month after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date.
F2: The option shall vest in twelve equal monthly installments, beginning one month after the grant date.
OneIM Acquisition Corp.
Report date January 13, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary shares, par value $0.0001 per shareSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-01-13 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the Issuer's registration statement on Form S-1 (No. 333-292356), the shares of Class B ordinary shares will automatically convert into shares of Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis subject to certain adjustments and have no expiration date. F2: These shares represent the shares of Class B ordinary shares held directly by the Reporting Person, acquired pursuant to a share transfer agreement by and between the OneIM Sponsor LLC and the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Issuer's registration statement on Form S-1 (No. 333-292356), the shares of Class B ordinary shares will automatically convert into shares of Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis subject to certain adjustments and have no expiration date.
F2: These shares represent the shares of Class B ordinary shares held directly by the Reporting Person, acquired pursuant to a share transfer agreement by and between the OneIM Sponsor LLC and the Issuer.
Sarissa Capital Acquisition Corp.
Report date October 20, 2020 · Filed October 20, 2020
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2026 Filed May 6, 2026 20:15 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $22.99 | $0.00 |
DisclosureSEC source: 0001193125-26-209015 · ownership.xml · derivative · entry 2 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-05-03 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability. Read SEC document |
| May 04, 2026 Filed May 6, 2026 20:15 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 9,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-209015 · ownership.xml · nonDerivative · entry 1 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,492 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability. Read SEC document |
| May 19, 2025 Filed May 22, 2025 01:35 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $18.63 | $0.00 |
DisclosureSEC source: 0001104659-25-051748 · tm2515701-2_4seq1.xml · derivative · entry 2 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-05-18 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2025 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| May 19, 2025 Filed May 22, 2025 01:35 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 12,077 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-051748 · tm2515701-2_4seq1.xml · nonDerivative · entry 1 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,706 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2025 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 18, 2025 Filed Apr 23, 2025 01:00 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionRestricted Stock Unit · Derivative | 838 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-056925 · ownership.xml · derivative · entry 3 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,676 Underlying: American Depositary Shares · 838 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion. F1 · shares: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F2 · derivative.exercise_date: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted an award that vests in three equal installments on each of April 18, 2025, April 18, 2026 and April 18, 2027 F3 · derivative.expiration_date: Not applicable F1 · derivative.underlying: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F1 · derivative.underlying_shares: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F1 · balance_after: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. Read SEC document |
| April 18, 2025 Filed Apr 23, 2025 01:00 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Tax withholdingAmerican Depositary Shares | 437 | $9.11 | $3,981.07 |
DisclosureSEC source: 0000950170-25-056925 · ownership.xml · nonDerivative · entry 2 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 401 F1 · security: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F4 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F1 · shares: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F1 · balance_after: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. Read SEC document |
| April 18, 2025 Filed Apr 23, 2025 01:00 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionAmerican Depositary Shares | 838 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-056925 · ownership.xml · nonDerivative · entry 1 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F2 · kind: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted an award that vests in three equal installments on each of April 18, 2025, April 18, 2026 and April 18, 2027 F1 · shares: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F3 · price: Not applicable F1 · balance_after: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:54 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $16.16 | $0.00 |
DisclosureSEC source: 0001104659-24-073442 · tm2417570-1_4seq1.xml · derivative · entry 2 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-16 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2024 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:54 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 13,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073442 · tm2417570-1_4seq1.xml · nonDerivative · entry 1 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,629 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2024 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 18, 2024 Filed Apr 19, 2024 20:35 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantRestricted Stock Unit · Derivative | 50,287 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-046052 · ownership.xml · derivative · entry 2 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,287 Underlying: Ordinary Shares · 50,287 shares Expires not disclosed F3 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F4 · derivative.exercise_date: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted an award of 50,287 RSUs under the Plan and the Policy. These RSUs vest in three equal installments on each of April 18, 2025, April 18, 2026 and April 18, 2027. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 18, 2024 Filed Apr 19, 2024 20:35 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantStock Option (right to buy) · Derivative | 179,795 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0000950170-24-046052 · ownership.xml · derivative · entry 1 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,795 Underlying: Ordinary Shares · 179,795 shares Expires 2034-04-18 F1 · derivative.exercise_date: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted an option to purchase 179,795 Ordinary Shares under the Plan and the Policy. The shares subject to this option shall vest and become exercisable over three years, with 33% to vest on the first anniversary of the grant date and the remaining balance vesting in equal quarterly installments over the subsequent two years on the first day of each April, July, October and January. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| July 21, 2023 Filed Jul 22, 2023 01:15 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantRestricted Stock Units · Derivative | 55,804 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-033911 · ownership.xml · derivative · entry 4 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,804 Underlying: Ordinary Shares · 55,804 shares Expires not disclosed F4 · security: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F7 · derivative.exercise_date: On July 21, 2023, following the conclusion of the Issuer's annual general meeting of shareholders for 2023, the Reporting Person was granted an award of 55,804 RSUs under the Plan and the Policy. These RSUs vest in full upon the earlier of the one-year anniversary of the grant date and the annual general meeting of shareholders in such anniversary year. The RSUs are subject to deferred settlement upon the director's separation of service with the Issuer. F6 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| July 21, 2023 Filed Jul 22, 2023 01:15 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantRestricted Stock Units · Derivative | 94,866 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-033911 · ownership.xml · derivative · entry 3 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,866 Underlying: Ordinary Shares · 94,866 shares Expires not disclosed F4 · security: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F5 · derivative.exercise_date: In connection with the Reporting Person's initial appointment to the Issuer's board of directors, on July 21, 2023 the Reporting Person was granted a one-time grant of 94,866 RSUs under the Plan and the Policy. These RSUs vest in equal annual installments over three years from the date of the Reporting Person's initial appointment to the Issuer's board of directors. The RSUs are subject to deferred settlement upon the director's separation of service with the Issuer. F6 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| July 21, 2023 Filed Jul 22, 2023 01:15 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantStock Option (Right to Buy) · Derivative | 167,411 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0000950170-23-033911 · ownership.xml · derivative · entry 2 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,411 Underlying: Ordinary Shares · 167,411 shares Expires 2033-07-21 F3 · derivative.exercise_date: On July 21, 2023, following the conclusion of the Issuer's annual general meeting of shareholders for 2023, the Reporting Person was granted an option to purchase 167,411 Ordinary Shares under the Plan and the Policy. This option shall vest and become exercisable upon the earlier of the one-year anniversary of the grant date and the annual general meeting of shareholders in such anniversary year. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| July 21, 2023 Filed Jul 22, 2023 01:15 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantStock Option (Right to Buy) · Derivative | 284,598 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0000950170-23-033911 · ownership.xml · derivative · entry 1 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,598 Underlying: Ordinary Shares · 284,598 shares Expires 2033-07-21 F1 · derivative.exercise_date: In connection with the Reporting Person's initial appointment to the Issuer's board of directors, on July 21, 2023 the Reporting Person was granted a one-time option to purchase 284,598 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan") and the Non-Employee Director Compensation Policy, as revised in May 2023 (the "Policy"). This option shall vest and become exercisable in equal annual installments over three years from the date of the Reporting Person's initial appointment to the Issuer's board of directors. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:50 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $13.64 | $0.00 |
DisclosureSEC source: 0001104659-23-064210 · tm2316873-2_4seq1.xml · derivative · entry 2 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-21 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2023 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:50 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 16,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-064210 · tm2316873-2_4seq1.xml · nonDerivative · entry 1 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,706 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2023 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 22:49 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $17.79 | $0.00 |
DisclosureSEC source: 0001567619-22-009043 · doc1.xml · derivative · entry 2 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-04-24 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 22:49 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 12,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-009043 · doc1.xml · nonDerivative · entry 1 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,211 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| May 14, 2021 Filed May 21, 2021 00:14 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 17,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-010828 · doc1.xml · nonDerivative · entry 1 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,564 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") upon the conclusion of the Issuer's 2021 annual meeting of stockholders. 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:11 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 16,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-008543 · doc1.xml · nonDerivative · entry 1 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,082 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 24, 2019 Filed May 25, 2019 01:58 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 16,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-031863 · a4.xml · nonDerivative · entry 1 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,165 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 16:31 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.33 | $0.00 |
DisclosureSEC source: 0001104659-18-051507 · a4.xml · derivative · entry 1 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2028-08-09 F1 · derivative.exercise_price: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date. F2 · derivative.exercise_date: The option shall vest in twelve equal monthly installments, beginning one month after the grant date. Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 20:10 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 14,249 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005884 · edgar.xml · nonDerivative · entry 1 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,766 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 22:43 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 10,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002084 · edgar.xml · nonDerivative · entry 1 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,517 Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 16:02 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantStock Option (Right to Buy) · Derivative | 9,600 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001104659-17-048839 · a4.xml · derivative · entry 1 DiPaolo Mark · CIK 0001669816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Shares · 9,600 shares Expires 2027-08-01 F1 · derivative.exercise_price: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date. F2 · derivative.exercise_date: The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.